Polyneuropathy

Jan 14, 2019

Intravenous Immunoglobulin (IVIG) Market to Reach $12.63 Bn, Globally, by 2022 at 7.1% CAGR, Says AMR

Nov 15, 2018

Immunoglobulin Market to Reach $17.50 Bn, Globally, by 2025, at 7.5% CAGR, Says Allied Market Research

Aug 10, 2018

FDA approves first-of-its kind targeted RNA-based therapy to treat a rare disease

Apr 20, 2018

CSL Behring, Leader in Rare Diseases, Showcases Innovations in Neuromuscular Medicine (NMM) at the 2018 American Academy of Neurology Annual Meeting

Mar 16, 2018

FDA Approves Hizentra® (Immune Globulin Subcutaneous [Human] 20% Liquid) for the Treatment of Patients With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Nov 09, 2017

Lancet Neurology Publishes Results from CSL Behring Phase III Study of Hizentra® (Immune Globulin Subcutaneous [Human] 20% liquid) as Maintenance Therapy in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Sep 14, 2017

CSL Behring Announces FDA Approval of Privigen® [Immune Globulin Intravenous (Human), 10% Liquid] for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Adults